LENZ Therapeutics, Inc.
NASDAQ:LENZBiotechnology
-$0.42 today
- Market cap
- $100.86M
- Beta
- 1.47
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.48
Volume 0.62M
Average 0.89M
LENZ EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
LENZ Therapeutics, Inc.NASDAQ: LENZ
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$41.38M, compared with -$14.58M a year earlier. Trailing-twelve-month EBITDA was -$108.13M.
Context
- EBITDA amounted to 426.1% of revenue in FY2025.
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of -$115.79M (-42.4%) for the fiscal year ending Dec 2026, a step up from the -63.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$41.38M-15.6% QoQ
- Last fiscal yearDec 2025
- -$81.34M-63.6% YoY
- LTMMar 2026
- -$108.13M-126.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -183.7% | -128.6% | +55.2 pp |
| 1 year | -63.6% | -42.4% | +21.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (81.34M) USD
- Year-over-year change
- -63.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (81.34M) | -63.6% |
| FY2024 | 2024-12-31 | (49.71M) | +29.1% |
| FY2023 | 2023-12-31 | (70.13M) | -570.7% |
| FY2022 | 2022-12-31 | (10.46M) | +85.1% |
| FY2021 | 2021-12-31 | (70.03M) | — |
EBITDA vs competitors
How LENZ compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -126.9% is the 10th highest of 11, against a peer median of -4.6%.
- EBITDA amounts to 515.2% of revenue for LENZ, versus a peer median of 62.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $160.85M USD | +305.5% | — | 84.0% | |
| FY2025 | -€12.07M EUR | +82.2% | — | 40.7% | |
| LTM Mar 2026 | -$36.95M USD | +67.7% | — | 18.8% | |
| LTM Jun 2026 | -$55.57M USD | +77.9% | — | 26.6% | |
| LTM Mar 2026 | -$55.86M USD | -33.8% | — | — | |
| LTM Mar 2026 | -$81.45M USD | -11.6% | — | — | |
| LTM Mar 2026 | -$108.13M USD | -126.9% | — | 515.2% | |
| LTM Mar 2026 | -$129.27M USD | -25.5% | — | — | |
| LTM Mar 2026 | -$130.56M USD | -36.2% | — | — | |
| LTM Mar 2026 | -$190.9M USD | +2.4% | — | 4732.2% | |
SPRYARS Pharmaceuticals, Inc. | LTM Mar 2026 | -$192.17M USD | -1179.9% | — | 194.1% |
| Peer median (excluding LENZ) | — | -4.6% | — | 62.4% | |
Competitors are the stored peer set for LENZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 15M | 0 | 0 | 19.09M |
| Cost of Revenue | 734K | 0 | 0 | 58K | 705K |
| Gross Profit | (734K) | 15M | 0 | (58K) | 18.38M |
| Gross Margin | — | 100.0% | — | — | 96.3% |
| Research & Development | 37.93M | 21.13M | 59.5M | 29.8M | 18.67M |
| Selling, General & Admin | 21.78M | 4.36M | 12.93M | 28.75M | 90.85M |
| Operating Expenses | 59.71M | 25.48M | 72.43M | 58.55M | 109.52M |
| Depreciation & Amortization | 734K | 8K | 15K | 58K | 287K |
| EBITDA | (70.03M) | (10.46M) | (70.13M) | (49.71M) | (81.34M) |
| EBITDA Margin | — | -69.7% | — | — | -426.1% |
| Operating Income | (60.44M) | (10.48M) | (72.43M) | (58.61M) | (91.14M) |
| Operating Margin | — | -69.9% | — | — | -477.5% |
| Interest Income | 0 | 0 | 2.19M | 8.55M | 9.76M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (10.32M) | 19K | 2.28M | 8.84M | 9.51M |
| Income Before Tax | (70.76M) | (10.46M) | (70.15M) | (49.77M) | (81.63M) |
| Pre-Tax Margin | — | -69.8% | — | — | -427.6% |
| Income Tax Expense | 0 | 347K | (179K) | 1K | 502K |
| Net Income | (70.76M) | (10.81M) | (69.97M) | (49.77M) | (82.13M) |
| Net Margin | — | -72.1% | — | — | -430.3% |
| EPS (Basic) | (8.54) | (12.89) | (15.30) | (2.34) | (2.85) |
| EPS (Diluted) | (8.54) | (12.89) | (15.30) | (2.34) | (2.85) |
| Weighted Avg Shares | 8.29M | 7.84M | 8.15M | 21.28M | 28.81M |
| Weighted Avg Shares (Diluted) | 8.29M | 7.84M | 8.15M | 21.28M | 28.81M |
LENZ Therapeutics, Inc.
NASDAQ:LENZ
Intrinsic Alpha fair value
Locked
Current Price
$3.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.